The proportion of dyslipidemia in systemic lupus erythematosus patient and distribution of correlated factors.

LK Wijaya, YI Kasjmir, N Sukmana, I Subekti… - Acta Medica …, 2005 - europepmc.org
LK Wijaya, YI Kasjmir, N Sukmana, I Subekti, J Prihartono
Acta Medica Indonesiana, 2005europepmc.org
Aim To understand the proportion of dyslipidemia in systemic lupus erythematosus (SLE)
patients and the influencing factors of dyslipidemia. Methods AN observational, cross-
sectional study was conducted on new and longstanding SLE patients who had been
diagnosed based on ARA criteria 1982 with 1997 revision. They had been hospitalized and
treated at Department of Internal Medicine, Cipto Mangunkusumo National Central General
Hospital and the other private Hospitals in Jakarta, ie Kramat Hospital in July-November …
Aim
To understand the proportion of dyslipidemia in systemic lupus erythematosus (SLE) patients and the influencing factors of dyslipidemia.
Methods
AN observational, cross-sectional study was conducted on new and longstanding SLE patients who had been diagnosed based on ARA criteria 1982 with 1997 revision. They had been hospitalized and treated at Department of Internal Medicine, Cipto Mangunkusumo National Central General Hospital and the other private Hospitals in Jakarta, ie Kramat Hospital in July-November 2003. The sample was selected by non probability sampling method with consecutive sampling technique. Every participant underwent history taking, physical and laboratory examination.
Results
There were 77 patients satisfying the inclusion criteria. The proportion of dyslipidemia in this study was 75.3%. By confidence interval of 95%, the dyslipidemia in SLE patient was 65.3%-84.6%. The distribution of lipid profile in sample population were 43% with total cholesterol> or= 200 mg/dL, 26% with HDL cholesterol level< 40 mg/dL, 26.4% with LDL cholesterol level> or= 130 mg/dl and 44.2% with triglycerides serum level> or= 150 mg/dL. The characteristics of influencing factors in dyslipidemia prevalence for sample population consisted of 24.7% with renal involvement, 53.2% with> or= 3 years illness periods, 26% had received> or= 30 mg/day prednisone, 94.8% had not received chloroquines, and 58.4% had illness activity of Mex-SLEDAI> or= 2. By bivariate analysis, we found that illness period< 3 years tends to affect dyslipidemia with OR value of 12.04 (CI 95%, 2.54-57.05, p= 0.001). After conducting multivariate analysis by backward methods, it appears that only one significant influencing factor of dyslipidemia prevalence in SLE patient ie Illness period od< 3 years with OR value 12.04 (CI 95% 2.54-57.05, p= 0.001).
Conclusion
Illness period of 3 years is represent a significant correlative factor for dyslipedemia prevalence. Prednisone> or= 30 mg/dL is the correlative factor for total cholesterol> or= 200 mg. dL and triglycerides> or= 150 mg/dL. Mex-SLEDAI> or= 2 is the corrective factor for HDL cholesterol< 40 mg/dL.
europepmc.org
以上显示的是最相近的搜索结果。 查看全部搜索结果